Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Affimed NV (EM) AFMDQ

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24... see more

Bullboard (EXPM:AFMDQ)

View:
User Avatar Image
(187)
•••
  • coolfooldumbguyX
Post by coolfooldumbguyon Dec 05, 2024 1:58pm

Using technical analysis for this one.

Buy Order was filled today at $2.43 cents per share,so good luck to all of us shareholders out there.
User Avatar Image
(59)
•••
  • NibinatorX
Post by Nibinatoron Jun 12, 2024 10:29am

BUY BUY BUY BUY BUY

Big time news
User Avatar Image
(59)
•••
  • NibinatorX
Post by Nibinatoron Jun 12, 2024 10:29am

BUY BUY BUY BUY BUY

Big time news
Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}

At the Bell logo
A daily snapshot of everything
from market open to close.

Podcasts